Why the study?
To review existing literature to determine whether S-ICD is a safe alternative to TV-ICD and identify which patient populations should receive S-ICD over TV-ICD.
Is the subcutaneous implantable cardioverter defibrillator (S-ICD) a safe alternative to the transvenous implantable cardioverter defibrillator (TV-ICD) for the prevention of sudden cardiac death?
Is the subcutaneous implantable cardioverter defibrillator (S-ICD) a safe alternative to the transvenous implantable cardioverter defibrillator (TV-ICD) for the prevention of sudden cardiac death?
Answers are grounded in this paper and cite their sources.
This review evaluates the safety and appropriate patient selection for subcutaneous versus transvenous implantable cardioverter defibrillators.
Over the past decade, the emergence of the subcutaneous implantable cardioverter defibrillator (S-ICD) has provided cardiologists with an option to provide both primary or secondary prevention treatment of sudden cardiac death (SCD) without the associated risks that come with the use of intracardiac leads. S-ICD may prove to be a useful option in those who are young, have thromboembolic risk, immunodeficiency states, unfavorable anatomy due to adult congenital heart disease (ACHD). This article reviews the existing literature to determine whether S-ICD can prove to be a safe alternative in comparison to Transvenous implantable cardioverter defibrillator (TV-ICD) and in which patient population should S-ICD be considered over TV-ICD.
No takes yet. Share an insight, caveat, or question.
Savarimuthu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: